Clinical-stage biopharmaceutical company Anavex Life Sciences has initiated a long-term extension study for patients with early Alzheimer’s disease (AD) and treated with ANAVEX2-73 (blarcamesine).

Blarcamesine is an orally available, small-molecule activator of the sigma-1 receptor. It is indicated a play a key role in restoring neural cell homeostasis and promoting neuroplasticity.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The open label study, ATTENTION-AD, is an extension of the ongoing Phase IIb/III ANAVEX2-73-AD-004 clinical study. Phase IIb/III is a placebo-controlled trial conducted over 48 weeks.

Principal investigator for both studies Stephen Macfarlane said: “This is an important development as the patients who have completed the main study, ANAVEX2-73-AD-004, are consistently expressing the wish to gain ongoing access to this investigational therapy.”

ATTENTION-AD will be carried out for two years and will involve AD patients who participated in the ANAVEX2-73-AD-004 study.

Patients can enrol in the extension study only after completing the placebo-controlled Phase IIb/III trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ATTENTION-AD will provide additional tolerability and efficacy data and will be performed together with the Phase IIb/III ANAVEX2-73-AD-004 study.

Anavex chief executive officer Christopher U Missling said: “People living with Alzheimer’s disease desperately need new therapies and ATTENTION-AD reflects our commitment to the patients who participated in the Phase IIb/III ANAVEX 2-73-AD-004 study and who have contributed enormously to the development of a potential new medicine for patients with early Alzheimer’s disease.

“This study will provide supplemental data on ANAVEX 2-73 (blarcamesine).”

The company’s ANAVEX 2-73 has already completed a successful Phase IIa clinical trial for AD.